Blog Posts

Jean-Charles Soria: Cancer Cachexia – An Underdiagnosed, Lethal Syndrome

Photo: Depositphotos

Aug 5, 2025, 06:30

Jean-Charles Soria: Cancer Cachexia – An Underdiagnosed, Lethal Syndrome

Jean-Charles Soria, Amgen’s senior vice president of Oncology within Global Development, shared an article on X:

“Cancer cachexia equals to an underdiagnosed, lethal syndrome.

Affects up to 80% in pancreatic CA, 40% in lung.
It’s not just weight loss—think systemic inflammation, altered metabolism, fat/muscle wasting.
GDF-15, IL-6, activin A are key molecular drivers.
A major unmet need in cancer patients.”

Title: Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies

Authors: Kexin Koh, Rachel Scott, Elizabeth M. Cespedes Feliciano, Tobias Janowitz, Marcus D. Goncalves, Eileen P. White, Barry J.A. Laird, Kerstin Haase, and Mariam Jamal-Hanjani

Read The Full Article at Cancer Discovery.

Jean-Charles Soria: Cancer Cachexia - An Underdiagnosed, Lethal Syndrome

More posts featuring Jean-Charles Soria.

and Mariam Jamal-Hanjani Anorexia Barry J.A. Laird cancer cancer cachexia Eileen P. White Elizabeth M. Cespedes Feliciano Jean-Charles Soria Kerstin Haase Kexin Koh Marcus D. Goncalves OncoDaily Oncology Rachel Scott Tobias Janowitz

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...